Health Canada

 
News Articles for Health Canada top ^
BioMarin Announces Health Canada Approval of VIMIZIM™ (elosulfase alfa) for the Treatment of Morquio A Syndrome Canada NewsWire Approval delivers first pharmaceutical therapy for children and adults with ultra-rare, life-limiting disorder TORONTO , July 7, 2014 /CNW/ - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that Health Canada has approved VIMIZIM™(elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome.
Sign-up for BioMarin Announces Health Canada Approval of VIMIZIM™ (elosulfase alfa) for the Treatment of Morquio A Syndrome investment picks
2014/8/6
Health Canada Approves ABRAXANE® Plus Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Cancer Canada NewsWire MISSISSAUGA, ON , August 6, 2014 /CNW/ - Health Canada has approved Pr ABRAXANE ® for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab ® ] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer.
Sign-up for Health Canada Approves ABRAXANE® Plus Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Cancer investment picks
Health Canada Approves Eloctate™, the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A Canada NewsWire MISSISSAUGA, ON , Aug.
Sign-up for Health Canada Approves Eloctate™, the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A investment picks
2014/8/21
IMRIS receives Health Canada licensing for integrating latest generation MR scanners within VISIUS Surgical Theatre Canada NewsWire Core MRI technology provides most advanced scanners for highest intraoperative image quality and best workflow available WINNIPEG , Aug.
Sign-up for IMRIS receives Health Canada licensing for integrating latest generation MR scanners within VISIUS Surgical Theatre investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that it has received a No Objection Letter (“NOL”) from Health Canada to conduct a Phase 3 registration trial of Rhopressa TM , a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension in Canada.
Sign-up for Aerie Pharmaceuticals, Inc. Receives Health Canada “No Objection Letter” to Commence Phase 3 Registration Trial of RhopressaTM in Patients with Glaucoma in Canada investment picks
2014/8/25
http://media.marketwire.com/attachments/201408/78612_cleantechlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140085&ProfileId=051205&sourceType=1 MADISON HEIGHTS, MI --
Sign-up for CEN Biotech Announces the Completion of Its Pre-License Inspection by Health Canada investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the Company’s Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro TM as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada.
Sign-up for ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application investment picks
2014/8/21
Core MRI technology provides most advanced scanners for highest intraoperative image quality and best workflow available WINNIPEG , Aug.
Sign-up for IMRIS receives Health Canada licensing for integrating latest generation MR scanners within VISIUS Surgical Theatre investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Health Canada
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Health Businesses  |  Next: Health Care